US bill aims to tackle rise in false patent marking suits
This article was originally published in SRA
A new bill introduced in the US House of Representatives aims to restrict the penalties that are being awarded to plaintiffs that have sued companies for alleged false patent markings1,2. The Patent Lawsuit Reform Act of 2010, if signed into law, would bring relief to companies across all sectors – including pharmaceutical and medtech entities – that have been flooded with such lawsuits in the recent past.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.